| Year |
Citation |
Score |
| 2021 |
Huang YH, Hsu KH, Chin CS, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Chang GC. The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma. Cancer Research and Treatment. PMID 34352999 DOI: 10.4143/crt.2021.671 |
0.319 |
|
| 2021 |
Lee PH, Chen KC, Hsu KH, Huang YH, Tseng JS, Yang TY, Chang GC. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients. Anti-Cancer Drugs. PMID 34232936 DOI: 10.1097/CAD.0000000000001107 |
0.341 |
|
| 2021 |
Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, Hsia TC, Lin SH, Wu KL, Yang CT, Su WC, Chu YC, Wang CC, Liao WY, Lin YT, ... ... Chang GC, et al. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Therapeutic Advances in Medical Oncology. 13: 17588359211018022. PMID 34093743 DOI: 10.1177/17588359211018022 |
0.362 |
|
| 2021 |
Su SF, Liu CH, Cheng CL, Ho CC, Yang TY, Chen KC, Hsu KH, Tseng JS, Chen HW, Chang GC, Yu SL, Li KC. Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. Jco Precision Oncology. 5. PMID 34036228 DOI: 10.1200/PO.20.00151 |
0.303 |
|
| 2021 |
Park K, Chang GC, Curigliano G, Lim WT, Soo RA, Molina-Vila MA, Cattan V, Darville H, Gandossi E, Smutna V, Sudey I, Viteri S. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. Lung Cancer (Amsterdam, Netherlands). 155: 127-135. PMID 33798902 DOI: 10.1016/j.lungcan.2021.03.012 |
0.35 |
|
| 2021 |
Hsu KH, Huang JW, Tseng JS, Chen KW, Weng YC, Yu SL, Yang TY, Huang YH, Chen JJW, Chen KC, Chang GC. Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. Oncotargets and Therapy. 14: 2139-2148. PMID 33790577 DOI: 10.2147/OTT.S300267 |
0.333 |
|
| 2021 |
Chang GC, Lam DC, Tsai CM, Chen YM, Shih JY, Aggarwal S, Wang S, Kim SW, Kim YC, Wahid I, Li R, Lim DW, Sriuranpong V, Chan RT, Lorence RM, et al. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. International Journal of Clinical Oncology. PMID 33783657 DOI: 10.1007/s10147-021-01869-0 |
0.342 |
|
| 2020 |
Wu SG, Chiang CL, Liu CY, Wang CC, Su PL, Hsia TC, Shih JY, Chang GC. An Observational Study of Acquired T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. Frontiers in Oncology. 10: 1481. PMID 33014788 DOI: 10.3389/fonc.2020.01481 |
0.326 |
|
| 2020 |
Chih-Hsin Yang J, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, et al. Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32916310 DOI: 10.1016/J.Jtho.2020.09.001 |
0.311 |
|
| 2020 |
Tseng JS, Hsu KH, Zheng ZR, Yang TY, Chen KC, Huang YH, Su KY, Yu SL, Chang GC. Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment. Oncology. 1-9. PMID 32894845 DOI: 10.1159/000509664 |
0.318 |
|
| 2020 |
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, ... ... Chang GC, et al. Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. The New England Journal of Medicine. PMID 32469185 DOI: 10.1056/NEJMoa2004407 |
0.344 |
|
| 2020 |
Chen MC, Chen KC, Chang GC, Lin H, Wu CC, Kao WH, Teng CJ, Hsu SL, Yang TY. RAGE acts as an oncogenic role and promotes the metastasis of human lung cancer. Cell Death & Disease. 11: 265. PMID 32327633 DOI: 10.1038/s41419-020-2432-1 |
0.336 |
|
| 2020 |
Hsiao TF, Wang CL, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ. Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32156745 DOI: 10.1158/1078-0432.CCR-19-3972 |
0.334 |
|
| 2020 |
Chen YM, Chih-Hsin Yang J, Su WC, Chong IW, Hsia TC, Lin MC, Chang GC, Chiu CH, Ho CC, Wu SY, Hung JY, Wang CC, Yang TY, Yu CJ. Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 32094063 DOI: 10.1016/j.jfma.2020.01.004 |
0.317 |
|
| 2020 |
Huang CY, Hsu LH, Chen CY, Chang GC, Chang HW, Hung YM, Liu KJ, Kao SH. Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy. Cancers. 12. PMID 31936895 DOI: 10.3390/cancers12010181 |
0.303 |
|
| 2019 |
Lai CL, Wei YF, Hsia TC, Chang GC, Wu JT, Chen JY, Chen YM. S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan. Asia-Pacific Journal of Clinical Oncology. PMID 31773897 DOI: 10.1111/ajco.13294 |
0.315 |
|
| 2019 |
Marinis F, Wu YL, de Castro G, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, et al. ASTRIS: a global real-world study of osimertinib in >3000 patients with T790M positive non-small-cell lung cancer. Future Oncology (London, England). PMID 31339357 DOI: 10.2217/fon-2019-0324 |
0.319 |
|
| 2019 |
Hsu YC, Chang YH, Chang GC, Ho BC, Yuan SS, Li YC, Zeng JW, Yu SL, Li KC, Yang PC, Chen HY. Tumor mutation burden and recurrent tumors in hereditary lung cancer. Cancer Medicine. PMID 30941903 DOI: 10.1002/cam4.2120 |
0.307 |
|
| 2019 |
Chih-Hsin Yang J, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR-TKI therapy: CAURAL brief report. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30763730 DOI: 10.1016/j.jtho.2019.02.001 |
0.313 |
|
| 2019 |
Hung PF, Hong TM, Chang CC, Hung CL, Hsu YL, Chang YL, Wu CT, Chang GC, Chan NL, Yu SL, Yang PC, Pan SH. Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis. Journal of Experimental & Clinical Cancer Research : Cr. 38: 5. PMID 30612578 DOI: 10.1186/s13046-018-0996-8 |
0.311 |
|
| 2018 |
John T, Akamatsu H, Delmonte A, Su WC, Lee JS, Chang GC, Huang X, Jenkins S, Wu YL. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 126: 133-138. PMID 30527177 DOI: 10.1016/j.lungcan.2018.10.027 |
0.362 |
|
| 2018 |
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 30280657 DOI: 10.1056/NEJMoa1810171 |
0.361 |
|
| 2018 |
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Chih-Hsin Yang J, Lorence RM, Carrière P, Cseh A, Chang GC. Activity of Afatinib in Heavily Pretreated Patients with HER2 Mutation-Positive Advanced NSCLC: Findings from a Global Named Patient Use Program. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30096481 DOI: 10.1016/j.jtho.2018.07.093 |
0.329 |
|
| 2018 |
Yoh K, Nakagawa K, Chang G, Hosomi Y, Hsia T, Tamura T, Cheng R, Varea R, Enatsu S, Hayden Zimmermann A, Shih J. Effect of second-line ramucirumab in east Asian patients with refractory and aggressive disease: Subgroup analysis from REVEL and JVCG trials in non-small cell lung cancer Annals of Oncology. 29: ix144-ix145. DOI: 10.1093/ANNONC/MDY446.005 |
0.306 |
|
| 2018 |
Lu S, Camidge R, Yang C, Zhou J, Guo R, Chiu C, Chang G, Shiah H, Chen Y, Wang C, Berz D, Su W, Yang N, Wang Z, Fang J, et al. P1.01-62 The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients Journal of Thoracic Oncology. 13: S485. DOI: 10.1016/J.Jtho.2018.08.618 |
0.375 |
|
| 2018 |
Lai C, Wei Y, Hsia T, Chang G, Chen Y. P1.01-13 A Study of S-1 Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer Journal of Thoracic Oncology. 13: S464. DOI: 10.1016/J.JTHO.2018.08.569 |
0.343 |
|
| 2017 |
Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, Wang CL, Chen CY, Yen SH, Tsai CM, Huang MS, Ho CC, Yu CJ, Tsai YH, Chen JS, ... ... Chang GC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 8: 98384-98393. PMID 29228697 DOI: 10.18632/oncotarget.21842 |
0.316 |
|
| 2017 |
Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, et al. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. Lung Cancer (Amsterdam, Netherlands). 104: 58-64. PMID 28213001 DOI: 10.1016/j.lungcan.2016.12.002 |
0.344 |
|
| 2017 |
Akamatsu H, Delmonte A, John T, Su W, Lee J, Chang G, Huang X, Jenkins S, Dearden S, Wu Y. EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC) Annals of Oncology. 28: x128. DOI: 10.1093/ANNONC/MDX671.010 |
0.335 |
|
| 2017 |
Shih J, Yoh K, Hosomi Y, Chang G, Hsia T, Tamura T, Varea R, Nakamura T, Gallo J, Cheng R, Enatsu S, Nakagawa K. Ramucirumab in East Asian patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy: A pooled analysis of two randomized double-blind studies Annals of Oncology. 28: x122. DOI: 10.1093/annonc/mdx670.001 |
0.31 |
|
| 2017 |
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih J, Liao W, Gautschi O, Spataro V, Unk M, Yang J, Lorence R, Carrière P, Cseh A, Chang G. Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program Annals of Oncology. 28: v484-v485. DOI: 10.1093/ANNONC/MDX380.057 |
0.335 |
|
| 2016 |
Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. The Lancet. Oncology. PMID 27751847 DOI: 10.1016/S1470-2045(16)30508-3 |
0.325 |
|
| 2016 |
Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hsiao CF, Lee JH, Chen CY, Chen CH, Chang GC, Wang Z, Lo FY, Chen KY, Wang WC, Chen YM, et al. Genetic Modifiers of Progression-free Survival in Never-smoking Lung Adenocarcinoma Patients Treated with First-line TKIs. American Journal of Respiratory and Critical Care Medicine. PMID 27669169 DOI: 10.1164/rccm.201602-0300OC |
0.313 |
|
| 2016 |
Hsu KH, Tseng JS, Wang CL, Yang TY, Tseng CH, Chen HY, Chen KC, Tsai CR, Yang CT, Yu SL, Su KY, Yu CJ, Ho CC, Hsia TC, Wu MF, ... ... Chang GC, et al. Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. Oncotarget. PMID 27449093 DOI: 10.18632/oncotarget.10715 |
0.317 |
|
| 2016 |
Hsu CH, Tseng CH, Chiang CJ, Hsu KH, Tseng JS, Chen KC, Wang CL, Chen CY, Yen S-, Chiu CH, Huang MS, Yu CJ, Tsai YH, Chen JS, Tsai CM, ... ... Chang GC, et al. Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget. PMID 27191886 DOI: 10.18632/oncotarget.9338 |
0.355 |
|
| 2016 |
Huang YH, Hsu KH, Tseng JS, Chen KC, Su KY, Chen HY, Chang CS, Chen JJW, Yu SL, Chen HW, Yang TY, Chang GC. Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients Journal of Thoracic Disease. 8: 86-92. DOI: 10.3978/j.issn.2072-1439.2016.01.24 |
0.305 |
|
| 2015 |
Tseng CH, Chen KC, Hsu KH, Tseng JS, Ho CC, Hsia TC, Su KY, Wu MF, Chiu KL, Liu CM, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, ... ... Chang GC, et al. Different EGFR mutation profiles between the upper and lower lobes in lung adenocarcinoma. Carcinogenesis. PMID 26645716 DOI: 10.1093/carcin/bgv168 |
0.324 |
|
| 2015 |
Lai YH, Chen MH, Lin SY, Lin SY, Wong YH, Yu SL, Chen HW, Yang CH, Chang GC, Chen JJ. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways. Oncotarget. PMID 26312766 DOI: 10.18632/oncotarget.4761 |
0.324 |
|
| 2015 |
Lin SY, Chang HH, Lai YH, Lin CH, Chen MH, Chang GC, Tsai MF, Chen JJ. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer. Plos One. 10: e0123305. PMID 25955608 DOI: 10.1371/journal.pone.0123305 |
0.327 |
|
| 2015 |
Yang CH, Chou HC, Fu YN, Yeh CL, Cheng HW, Chang IC, Liu KJ, Chang GC, Tsai TF, Tsai SF, Liu HP, Wu YC, Chen YT, Huang SF, Chen YR. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. Biochimica Et Biophysica Acta. 1852: 1540-9. PMID 25912735 DOI: 10.1016/j.bbadis.2015.04.020 |
0.308 |
|
| 2015 |
Wang CC, Su KY, Chen HY, Chang SY, Shen CF, Hsieh CH, Hong QS, Chiang CC, Chang GC, Yu SL, Chen JJ. HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma. Plos One. 10: e0124191. PMID 25875824 DOI: 10.1371/journal.pone.0124191 |
0.327 |
|
| 2015 |
Hsu KH, Ho CC, Hsia TC, Tseng JS, Su KY, Wu MF, Chiu KL, Yang TY, Chen KC, Ooi H, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, ... ... Chang GC, et al. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. Plos One. 10: e0120852. PMID 25789627 DOI: 10.1371/journal.pone.0120852 |
0.308 |
|
| 2015 |
Hosgood HD, Song M, Hsiung CA, Yin Z, Shu XO, Wang Z, Chatterjee N, Zheng W, Caporaso N, Burdette L, Yeager M, Berndt SI, Landi MT, Chen CJ, Chang GC, et al. Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA). Human Genetics. 134: 333-41. PMID 25566987 DOI: 10.1007/S00439-014-1528-Z |
0.301 |
|
| 2015 |
Tseng JS, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Chen JJ, Chang GC. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 603-10. PMID 25514801 DOI: 10.1097/JTO.0000000000000443 |
0.302 |
|
| 2014 |
Mok TS, Tan E, Greater SL, Chang G, Yang JC, Gyuris J, Han M, Komarnitsky P, Payumo F, Pestano G, Roder J, Spinella D, Weng Z, Park K. 205PEFFICACY ANALYSIS OF GEFITINIB +/- FICLATUZUMAB IN SERUM PROTEOMIC BASED SUBGROUPS OF PATIENTS WITH PREVIOUSLY UNTREATED LUNG ADENOCARCINOMA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv70. PMID 28171152 DOI: 10.1093/annonc/mdu326.39 |
0.301 |
|
| 2014 |
Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Wu CW, Yang CT, Chen YM, ... Chang GC, et al. Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma. Plos One. 9: e107160. PMID 25215536 DOI: 10.1371/journal.pone.0107160 |
0.302 |
|
| 2014 |
Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC. Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. Oncotargets and Therapy. 7: 799-805. PMID 24920920 DOI: 10.2147/OTT.S62639 |
0.303 |
|
| 2013 |
Chang GC, Tsai CM, Hsia TC, Yang CH, Abdulnabi R, Blair JM, Linn C. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 112: 518-26. PMID 24060197 DOI: 10.1016/j.jfma.2012.02.030 |
0.325 |
|
| 2013 |
Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, ... ... Chang GC, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. The Lancet. Oncology. 14: 777-86. PMID 23782814 DOI: 10.1016/S1470-2045(13)70254-7 |
0.324 |
|
| 2012 |
Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. The Lancet. Oncology. 13: 539-48. PMID 22452895 DOI: 10.1016/S1470-2045(12)70086-4 |
0.363 |
|
| 2012 |
Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC. Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer (Amsterdam, Netherlands). 77: 128-33. PMID 22420950 DOI: 10.1016/j.lungcan.2012.02.012 |
0.366 |
|
| 2012 |
Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 433-40. PMID 22215752 DOI: 10.1200/JCO.2011.38.3224 |
0.326 |
|
| 2011 |
Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1663-9. PMID 21869714 DOI: 10.1097/JTO.0b013e318227816a |
0.342 |
|
| 2011 |
Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. Plos One. 6: e23756. PMID 21858220 DOI: 10.1371/journal.pone.0023756 |
0.35 |
|
| 2011 |
Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia-Pacific Journal of Clinical Oncology. 7: 34-40. PMID 21585706 DOI: 10.1111/j.1743-7563.2011.01400.x |
0.326 |
|
| 2011 |
Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, Thitiya S, Sriuranpong V, Thongprasert S, Chua DT, Moore N, Manegold C. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia-Pacific Journal of Clinical Oncology. 7: 4-12. PMID 21585703 DOI: 10.1111/J.1743-7563.2011.01397.X |
0.353 |
|
| 2009 |
Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC, Yang PC. A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7309-15. PMID 19920108 DOI: 10.1158/1078-0432.CCR-09-1572 |
0.313 |
|
| 2009 |
Jou YS, Lo YL, Hsiao CF, Chang GC, Tsai YH, Su WC, Chen YM, Huang MS, Chen HL, Chen CJ, Yang PC, Hsiung CA. Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. Lung Cancer (Amsterdam, Netherlands). 64: 251-6. PMID 19026460 DOI: 10.1016/j.lungcan.2008.09.014 |
0.309 |
|
| 2008 |
Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, Chu NM, Lai RS, Su WC, Tsao CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer (Amsterdam, Netherlands). 62: 78-84. PMID 18423781 DOI: 10.1016/j.lungcan.2008.02.023 |
0.342 |
|
| 2007 |
Chen KY, Hsiao CF, Chang GC, Tsai YH, Su WC, Perng RP, Huang MS, Hsiung CA, Chen CJ, Yang PC. Hormone replacement therapy and lung cancer risk in Chinese. Cancer. 110: 1768-75. PMID 17879370 DOI: 10.1002/cncr.22987 |
0.301 |
|
| 2007 |
Hsia T, Chang G, Chen Y, Lin M, Su W, Tsai C, Tsai C, Yang L. 6558 POSTER Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan European Journal of Cancer Supplements. 5: 375. DOI: 10.1016/S1359-6349(07)71386-1 |
0.324 |
|
| 2007 |
Hsia T, Chang G, Chen Y, Lin M, Su W, Tsai C, Tsai C, Yang L, Creeden J. PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN Value in Health. 10: A325. DOI: 10.1016/S1098-3015(10)65168-6 |
0.323 |
|
| 2006 |
Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, Su WP, Gow CH, Hsu C, Chang GC, Yang PC. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer. 107: 1873-82. PMID 16989002 DOI: 10.1002/cncr.22220 |
0.31 |
|
| 2006 |
Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1428-34. PMID 16549837 DOI: 10.1200/JCO.2005.04.3299 |
0.308 |
|
| 2006 |
Chang G, Tsai C, Chen K, Yu C, Shih J, Yang T, Lin C, Hsu J, Chiu C, Perng R, Yang P, Yang C. Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients Journal of Thoracic Oncology. 1: 520-525. DOI: 10.1016/S1556-0864(15)30353-1 |
0.344 |
|
| 2004 |
Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4646-8. PMID 15542815 DOI: 10.1200/JCO.2004.02.168 |
0.303 |
|
| 2004 |
Lee YL, Shih CM, Chiou HL, Shiau MY, Chang GC, Chang YH. Alteration of autoantibodies against p53 in Taiwanese lung cancer patients undergoing chemotherapy. Clinica Chimica Acta; International Journal of Clinical Chemistry. 349: 87-96. PMID 15469860 DOI: 10.1016/j.cccn.2004.06.008 |
0.311 |
|
| 2004 |
Wu MF, Wu WJ, Chang GC, Chen CY, Hu SW, Tsai WT, Lee H, Lin P. Increased expression of cytochrome P4501B1 in peripheral leukocytes from lung cancer patients. Toxicology Letters. 150: 211-9. PMID 15093676 DOI: 10.1016/j.toxlet.2004.01.006 |
0.312 |
|
| Show low-probability matches. |